新型コロナウイルスCOVID-19特講 2021

出版社: 中外医学社
著者:
発行日: 2021-01-20
分野: 臨床医学:内科  >  感染症/AIDS
ISBN: 9784498021341
電子書籍版: 2021-01-20 (1版1刷)
書籍・雑誌
≪全国送料無料でお届け≫
発送目安:約3営業日

2,970 円(税込)

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

2,970 円(税込)

商品紹介

2021年を迎えても収束の気配を見せないCOVID-19.最前線で闘う医療者に,新型コロナウイルスを正しく理解しようとする一般の方に,Dr.岡が再び最新情報を贈ります.ウイルス変異,重症化因子,PCR・抗原検査、治療薬・ワクチンなどの最新知見を踏まえ、全面的に書き改めるとともに,「症例編」には自験例を前提としたリアルな症例検討を収録.

目次

  • [講義編]
     ◆第1講 総論:疫学・ウイルス学
       はじめに
       新型コロナウイルスとは
       わかってきたウイルス感染・発症のメカニズム
       ウイルスの変異と弱毒化説・楽観説について
       みえてきた感染様式の実態
       臨床像
     ◆第2講 感染予防
       はじめに
       医療機関における感染予防の重要性
       医療施設における適切な予防策
       感染者の早期覚知,隔離
       適切な感染予防策の実施
       適切な環境消毒
       感染者の隔離解除
       濃厚接触に該当してしまった際の対応
       ワクチンについて
     ◆第3講 診断
       はじめに
       臨床症状
       検査による診断
     ◆第4講 治療
       はじめに
       わずかだが,確立されつつある治療ストラテジー
       治療において最も重要なこと
       重症化のメカニズムと対処法
       酸素療法
       治療方針の考え方
       レムデシビル
       ステロイド
       ロピナビル/リトナビル
       ヒドロキシクロロキン
       トシリズマブ
       ファビピラビル
       回復者血清
       その他

    [症例検討編]
     ◆症例1 発熱・咳嗽の40歳代男性
     ◆症例2 意識障害を呈した70歳代女性
     ◆症例3 発熱,倦怠感が持続する60歳代男性
     ◆症例4 発熱,全身倦怠感,咽頭痛を呈した70歳代女性
     ◆症例5 発熱,咳嗽,労作時呼吸困難を呈した50歳代男性

おすすめ商品

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

講義編

P.17 掲載の参考文献
1) Callaway E. The coronavirus is mutating-does it matter? Nature. 2020 ; 585 : 174-7. PMID : 32901123
2) Korber B, Fischer WM, Gnanakaran S, et al. Tracking changes in SARS-CoV-2 spike : evidence that D614G increases infectivity of the COVID-19 virus. Cell. 2020 ; 182 : 812-27.e19. PMID : 32697968
3) Vahidy FS, Drews AL, Masud FN, et al. Characteristics and outcomes of COVID-19 patients during initial peak and resurgence in the Houston Metropolitan area. JAMA. 2020 ; 324 : 998-1000. PMID : 32789492
4) Morawska L, Milton DK. It is time to address airborne transmission of COVID-19. Clin Infect Dis. 2020 Jul 6:ciaa939. PMID : 32628269
5) Shen Y, Li C, Dong H, et al. Community outbreak investigation of SARS-CoV-2 transmission among bus riders in eastern China. JAMA Intern Med. 2020 : e205225. PMID : 32870239
6) He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med. 2020 ; 26 : 672-5. Erratum in : Nat Med. 2020 ; 26 : 1491-3. PMID : 32296168
7) Cheng HY, Jian SW, Liu DP, et al ; Taiwan COVID-19 Outbreak Investigation Team. Contact tracing assessment of COVID-19 transmission dynamics in Taiwan and risk at different exposure periods before and after symptom onset. JAMA Intern Med. 2020 ; 180 : 1156-63. PMID : 32356867
8) Xiao AT, Tong YX, Zhang S. Profile of RT-PCR for SARS-CoV-2 : a preliminary study from 56 COVID-19 patients. Clin Infect Dis. 202 ; 71 : 2249-51. PMID : 32306036
9) Kimball A, Hatfield KM, Arons M, et al ; Public Health-Seattle & King County ; CDC COVID-19 Investigation Team. Asymptomatic and presymptomatic SARS-CoV-2 infections in residents of a long-term care skilled nursing facility-King County, Washington, March 2020. MMWR Morb Mortal Wkly Rep. 2020 ; 69 : 377-81. PMID : 32240128
10) Sakurai A, Sasaki T, Kato S, et al. Natural history of asymptomatic SARS-CoV-2 infection. N Engl J Med. 2020 ; 383 : 885-6. PMID : 32530584
11) Lipman M, Chambers RC, Singer M, et al. SARS-CoV-2 pandemic : clinical picture of COVID-19 and implications for research. Thorax. 2020 ; 75 : 614-6. PMID : 32461230
12) Yang R, Gui X, Xiong Y. Comparison of clinical characteristics of patients with asymptomatic vs symptomatic coronavirus disease 2019 in Wuhan, China. JAMA Netw Open. 2020 ; 3 : e2010182. Erratum in : JAMA Netw Open. 2020 ; 3 : e2014310. PMID : 32459353
13) Lee S, Kim T, Lee E, et al. Clinical course and molecular viral shedding among asymptomatic and symptomatic patients with SARS-CoV-2 infection in a community treatment center in the Republic of Korea. JAMA Intern Med. 2020 ; 180 : 1-6. PMID : 32780793
P.38 掲載の参考文献
1) Ing EB, Xu QA, Salimi A, et al. Physician deaths from corona virus disease (COVID-19). medRxiv 2020.04.05.20054494 ; doi : https://doi.org/10.1101/2020.04.05.20054494
2) Zhan M, Qin Y, Xue X, et al. Death from Covid-19 of 23 health care workers in China. N Engl J Med. 2020 ; 382 : 2267-8. PMID : 32294342
3) Sickbert-Bennett EE, Samet JM, Clapp PW, et al. Filtration efficiency of hospital face mask alternatives available for use during the COVID-19 pandemic. JAMA Intern Med. 2020 : e204221. PMID : 32780113
4) Arons MM, Hatfleld KM, Reddy SC, et al ; Public Health-Seattle and King County and CDC COVID-19 Investigation Team. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Engl J Med. 2020 ; 382 : 2081-90. PMID : 32329971
5) Brooks JT, Butler JC, Redfield RR. Universal masking to prevent SARS-CoV-2 transmission-The time is now. JAMA. 2020 Jul 14. PMID : 32663243
6) Wang X, Ferro EG, Zhou G, et al. Association between universal masking in a health care system and SARS-CoV-2 positivity among health care workers. JAMA. 2020 ; 324 : 703-4. PMID : 32663246
7) Chu DK, Akl EA, Duda S, et al ; COVID-19 Systematic Urgent Review Group Effort (SURGE) study authors. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19 : a systematic review and meta-analysis. Lancet. 2020 ; 395 : 1973-87. PMID : 32497510
8) Bhaskar ME, Arun S. SARS-CoV-2 infection among community health workers in India before and after use of face shields. JAMA. 2020 ; 324 : 1348-9. PMID : 32808979
10) Ong SWX, Tan YK, Chia PY, et al. Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient. JAMA. 2020 ; 323 : 1610-2. PMID : 32129805
11) Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med. 2020 ; 383 : 517-25. PMID : 32492293
12) Omer SB, Malani P, Del Rio C. The COVID-19 pandemic in the US : a clinical update. JAMA. 2020 ; 323 : 1767-8. PMID : 32250388
13) Folegatti PM, Ewer KJ, Aley PK, et al ; Oxford COVID Vaccine Trial Group. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 : a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020 ; 396 : 467-78. Erratum in : Lancet. 2020 ; 396 : 466. PMID : 32702298
14) Xia S, Duan K, Zhang Y, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes : interim analysis of 2 randomized clinical trials. JAMA. 2020 ; 324 : 951-60. PMID : 32789505
15) Corbett KS, Flynn B, Foulds KE, et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N Engl J Med. 2020 ; 383 : 1544-55. PMID : 32722908
P.62 掲載の参考文献
1) Oran DP, Topol EJ. Prevalence of asymptomatic SARS-CoV-2 infection : a narrative review. Ann Intern Med. 2020 ; 173 : 362-7. PMID : 32491919
2) Guan WJ, Ni ZY, Hu Y, et al ; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 ; 382 : 1708-20. PMID : 32109013
3) Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020 ; 382 : 1199-207. PMID : 31995857
4) Caputo ND, Strayer RJ, Levitan R. Early self-proning in awake, non-intubated patients in the emergency department : a single ED's experience during the COVID-19 pandemic. Acad Emerg Med. 2020 ; 27 : 375-8. PMID : 32320506
5) Giacomelli A, Pezzati L, Conti F, et al. Self-reported olfactory and taste disorders in patients with severe acute respiratory coronavirus 2 infection : a cross-sectional study. Clin Infect Dis. 2020 ; 71 : 889-90. PMID : 32215618
6) Menni C, Valdes AM, Freidin MB, et al. Loss of smell and taste in combination with other symptoms is a strong predictor of COVID-19 infection. medRxiv 2020.04.05. 20048421 ; doi : https://doi.org/10.1101/2020.04.05.20048421
7) Spinato G, Fabbris C, Polesel J, et al. Alterations in smell or taste in mildly symptomatic outpatients with SARS-CoV-2 infection. JAMA. 2020 ; 323 : 2089-90. PMID : 32320008
8) Cheung KS, Hung IFN, Chan PPY, et al. Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong cohort : systematic review and meta-analysis. Gastroenterology. 2020 ; 159 : 81-95. PMID : 32251668
9) Helms J, Kremer S, Merdji H, et al. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med. 2020 ; 382 : 2268-70. PMID : 32294339
10) Toscano G, Palmerini F, Ravaglia S, et al. Guillain-Barre syndrome associated with SARS-CoV-2. N Engl J Med. 2020 ; 382 : 2574-76. PMID : 32302082
11) Restivo DA, Centonze D, Alesina A, et al. Myasthenia gravis associated with SARS-CoV-2 infection. Ann Intern Med. 2020 Aug 10 : L20-0845. PMID : 32776781
12) Carfi A, Bernabei R, Landi F ; Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA. 2020 ; 324 : 603-5. PMID : 32644129
13) Tenforde MW, Kim SS, Lindsell CJ, et al ; IVY Network Investigators ; CDC COVID-19 Response Team ; IVY Network Investigators. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network-United States, March-June 2020. MMWR Morb Mortal Wkly Rep. 2020 ; 69 : 993-8. PMID : 32730238
14) Puntmann VO, Carerj ML, Wieters I, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020 ; 5 : 1265-73. PMID : 32730619
16) Piccirillo JF. Otolaryngology-head and neck surgery and COVID-19. JAMA. 2020 ; 324 : 1145-6. PMID : 32960254
17) Chiesa-Estomba CM, Lechien JR, Radulesco T, et al. Patterns of smell recovery in 751 patients affected by the COVID-19 outbreak. Eur J Neurol. 2020 Jul 16 : 10.1111/ene.14440. PMID : 32677329
18) Boscolo-Rizzo P, Borsetto D, Fabbris C, et al. Evolution of altered sense of smell or taste in patients with mildly symptomatic COVID-19. JAMA Otolaryngol Head Neck Surg. 2020 ; 146 : 729-32. PMID : 32614442
19) Ing EB, Xu QA, Salimi A, et al. Physician deaths from corona virus disease (COVID-19). medRxiv 2020.04.05.20054494 ; doi : https://doi.org/10.1101/2020.04.05.20054494
20) Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe covid-19. N Engl J Med. 2020 ; 382 : 2327-36. PMID : 32275812
21) Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 ; 395 : 497-506. Erratum in : Lancet. 2020 Jan 30. PMID : 31986264
23) Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med. 2020 ; 382 : e38. PMID : 32268022
24) Bowles L, Platton S, Yartey N, et al. Lupus anticoagulant and abnormal coagulation tests in patients with Covid-19. N Engl J Med. 2020 ; 383 : 288-90. PMID : 32369280
25) Kucirka LM, Lauer SA, Laeyendecker O, et al. Variation in false-negative rate of reverse transcriptase polymerase chain reaction-based SARS-CoV-2 tests by time since exposure. Ann Intern Med. 2020 ; 173 : 262-7. PMID : 32422057
26) Uchida S, Uno S, Uwamino Y, et al ; Keio Donner Project Team. CT screening for COVID-19 in asymptomatic patients before hospital admission. J Infect Chemother. 2020 Sep 29 : S1341-321X (20) 30345-7. PMID : 33172767
29) Yokota I, Shane PY, Okada K, et al. Mass screening of asymptomatic persons for SARS-CoV-2 using saliva. Clin Infect Dis. 2020 Sep 25 : ciaa1388. PMID : 32976596
30) Wyllie AL, Fournier J, Casanovas-Massana A, et al. Saliva or nasopharyngeal swab specimens for detection of SARS-CoV-2. N Engl J Med. 2020 ; 383 : 1283-6. PMID : 32857487
31) Nagura-Ikeda M, Imai K, Tabata S, et al. Clinical evaluation of self-collected saliva by quantitative reverse transcription-PCR (RT-qPCR), direct RT-qPCR, reverse transcription-loop-mediated isothermal amplification, and a rapid antigen test to diagnose COVID-19. J Clin Microbiol. 2020 ; 58 : e01438-20. PMID : 32636214
32) Williams E, Bond K, Zhang B, et al. Saliva as a noninvasive specimen for detection of SARS-CoV-2. J Clin Microbiol. 2020 ; 58 : e00776-20. PMID : 32317257
33) Kucharski AJ, Klepac P, Conlan AJK, et al ; CMMID COVID-19 working group. Effectiveness of isolation, testing, contact tracing, and physical distancing on reducing transmission of SARS-CoV-2 in difierent settings : a mathematical modelling study. Lancet Infect Dis. 2020 ; 20 : 1151-60. PMID : 32559451
34) 忽那賢志. 新型コロナのPCR検査陽性率数値をどう解釈すべきか. 2020年8月1日. https://news.yahoo.co.jp/byline/kutsunasatoshi/20200801-00190914/(Accessed 2020.11.25)
35) Wu J, Liu J, Zhao X, et al. Clinical characteristics of imported cases of coronavirus disease 2019 (COVID-19) in Jiangsu province : a multicenter descriptive study. Clin Infect Dis. 2020 ; 71 : 706-12. PMID : 32109279
36) Wu X, Cai Y, Huang X, et al. Co-infection with SARS-CoV-2 and Influenza A virus in patient with pneumonia, China. Emerg Infect Dis. 2020 ; 26 : 1324-6. PMID : 32160148
37) Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China : a retrospective cohort study. Lancet. 2020 ; 395 : 1054-62. Erratum in : Lancet. 2020 ; 395 : 1038. Erratum in : Lancet. 2020 ; 395 : 1038. PMID : 32171076
P.89 掲載の参考文献
2) Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 ; 395 : 497-506. Erratum in : Lancet. 2020 Jan 30. PMID : 31986264
3) Rawson TM, Moore LSP, Zhu N, et al. Bacterial and fungal co-infection in individuals with coronavirus : a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis. 2020 May 2 : ciaa530. PMID : 32358954
4) Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020 ; 18 : 1094-9. PMID : 32220112
5) Paranjpe I, Fuster V, Lala A, et al. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J Am Coll Cardiol. 2020 ; 76 : 122-4. PMID : 32387623
6) Nahum J, Morichau-Beauchant T, Daviaud F, et al. Venous thrombosis among critically ill patients with coronavirus disease 2019 (COVID-19). JAMA Netw Open. 2020 ; 3 : e2010478. PMID : 32469410
7) Rosen RJ. Thrombotic complications in critically ill patients with COVID-19. Thromb Res. 2020 ; 191 : 56. PMID : 32388068
11) Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020 ; 382 : 2327-36. PMID : 32275812
12) Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19 : a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020 ; 395 : 1569-78. Erratum in : Lancet. 2020 ; 395 : 1694. PMID : 32423584
13) Goldman JD, Lye DCB, Hui DS, et al ; GS-US-540-5773 Investigators. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med. 2020 ; 383 : 1827-37. PMID : 32459919
14) McCreary EK, Angus DC. Efficacy of remdesivir in COVID-19. JAMA. 2020 ; 324 : 1041-2. PMID : 32821934
15) Spinner CD, Gottlieb RL, Criner GJ, et al ; GS-US-540-5774 Investigators. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19 : a randomized clinical trial. JAMA. 2020 ; 324 : 1048-57. PMID : 32821939
16) Beigel JH, Tomashek KM, Dodd LE, et al ; ACTT-1 Study Group Members. Remdesivir for the treatment of Covid-19-final report. N Engl J Med. 2020 ; 383 : 1813-26. PMID : 32445440
17) 国立研究開発法人国立国際医療研究センター. 吸入ステロイド薬シクレソニド (販売名 : オルベスコ) のCOVID-19を対象とした特定臨床研究結果速報について. 2020年12月23日. https://www.ncgm.go.jp/pressrelease/2020/20201223_1.html (Accessed 2020/12/23)
18) RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19-preliminary report. N Engl J Med. 2020 Jul 17 : NEJMoa2021436. PMID : 32678530
19) WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, Diaz JV, et al. Association Between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19 : a meta-analysis. JAMA. 2020 ; 324 : 1330-41. PMID : 32876694
20) Siemieniuk RA, Bartoszko JJ, Ge L, et al. Drug treatments for COVID-19 : living systematic review and network meta-analysis. BMJ. 2020 Jul 30 ; 370 : m2980. Update in : BMJ. 2020 Sep 11 ; 370 : m3536. PMID : 32732190
21) Tomazini BM, Maia IS, Cavalcanti AB, et al ; COALITION COVID-19 Brazil III Investigators. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19 : the CoDEX randomized clinical trial. JAMA. 2020 ; 324 : 1307-16. PMID : 32876695
22) Jeronimo CMP, Farias MEL, Val FFA, et al ; Metcovid Team. Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19 (Metcovid) : a randomised, double-blind, phase IIb, placebo-controlled trial. Clin Infect Dis. 2020 Aug 12 : ciaa1177. PMID : 32785710
23) Salton F, Confalonieri P, Meduri GU, et al. Prolonged low-dose methylprednisolone in patients with severe COVID-19 pneumonia. Open Forum Infect Dis. 2020 ; 7 : ofaa421. PMID : 33072814
25) Borba MGS, Val FFA, Sampaio VS, et al ; CloroCovid-19 Team. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection : a randomized clinical trial. JAMA Netw Open. 2020 ; 3 : e208857. PMID : 32330277
26) Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020 ; 382 : 2411-8. PMID : 32379955
27) Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state. JAMA. 2020 ; 323 : 2493-502. PMID : 32392282
28) Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019 : open label, randomised controlled trial. BMJ. 2020 May 14 ; 369 : m1849. PMID : 32409561
29) Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med. 2020 ; 383 : 517-25. PMID : 32492293
30) Faguer S, Del Bello A, Abravanel F, et al. Tocilizumab for hemophagocytic syndrome in a kidney transplant recipient with COVID-19. Ann Intern Med. 2020 ; 173 : 501-3. PMID : 32432518
31) Capra R, De Rossi N, Mattioli F, et al. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. Eur J Intern Med. 2020 ; 76 : 31-5. PMID : 32405160
32) Schulert GS. Can tocilizumab calm the cytokine storm of COVID-19? Lancet Rheumatol. 2020 ; 2 : e449-51. PMID : 32835248
33) Hermine O, Mariette X, Tharaux PL, et al ; CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia : a randomized clinical trial. JAMA Intern Med. 2020 Oct 20 : e206820. PMID : 33080017
34) Huet T, Beaussier H, Voisin O, et al. Anakinra for severe forms of COVID-19 : a cohort study. Lancet Rheumatol. 2020 ; 2 : e393-400. PMID : 32835245
35) Bronte V, Ugel S, Tinazzi E, et al. Baricitinib restrains the immune dysregulation in patients with severe COVID-19. J Clin Invest. 2020 Nov 3 : 141772. PMID : 32809969
36) Salama C, Han J, Yau L, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2020 Dec 17. PMID : 33332779
37) Chen C, Zhang Y, Huang J, et al. Favipiravir versus Arbidol for COVID-19 : a randomized clinical trial. medRxiv 2020.03.17.20037432 ; doi : https://doi.org/10.1101/2020.03.17.20037432
38) Doi Y, Hibino M, Hase R, et al. A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19. Antimicrob Agents Chemother. 2020 ; 64 : e01897-20. PMID : 32958718
39) Ivashchenko AA, Dmitriev KA, Vostokova NV, et al. Avifavir for treatment of patients with moderate COVID-19 : interim results of a phase II/III multicenter randomized clinical trial. Clin Infect Dis. 2020 Aug 9 : ciaa1176. PMID : 32770240
40) Callaway E. Russia's fast-track coronavirus vaccine draws outrage over safety. Nature. 2020 ; 584 : 334-5. PMID : 32782400
41) Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020 ; 323 : 1582-9. PMID : 32219428
42) Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19 : a randomized clinical trial. JAMA. 2020 ; 324 : 460-70. Erratum in : JAMA. 2020 ; 324 : 519. PMID : 32492084
43) Simonovich VA, Burgos Pratx LD, Scibona P, et al ; PlasmAr Study Group. A randomized trial of convalescent plasma in Covid-19 severe pneumonia. N Engl J Med. 2020 Nov 24. PMID : 33232588
44) Khamis F, Al-Zakwani I, Al Hashmi S, et al. Therapeutic plasma exchange in adults with severe COVID-19 infection. Int J Infect Dis. 2020 ; 99 : 214-8. PMID : 32585284
45) Hamiel U, Kozer E, Youngster I. SARS-CoV-2 rates in BCG-vaccinated and unvaccinated young adults. JAMA. 2020 ; 323 : 2340-1. PMID : 32401274
46) Giamarellos-Bourboulis EJ, Tsilika M, Moorlag S, et al. Activate : randomized clinical trial of BCG vaccination against infection in the elderly. Cell. 2020 ; 183 : 315-23.e9. PMID : 32941801
47) Chan JF, Yao Y, Yeung ML, et al. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis. 2015 ; 212 : 1904-13. PMID : 26198719
48) Doi K, Ikeda M, Hayase N, et al ; COVID-UTH Study Group. Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19 : a case series. Crit Care. 2020 ; 24 : 392. PMID : 32620147
49) Freedberg DE, Conigliaro J, Wang TC, et al ; Famotidine Research Group. Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients : a propensity score matched retrospective cohort study. Gastroenterology. 2020 ; 159 : 1129-31.e3. PMID : 32446698
50) De Luca G, Cavalli G, Campochiaro C, et al. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation : a single-centre, prospective cohort study. Lancet Rheumatol. 2020 ; 2 : e465-73. PMID : 32835256
51) Lenze EJ, Mattar C, Zorumski CF, et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19 : a randomized clinical trial. JAMA. 2020 Nov 12 : e2022760. PMID : 33180097
52) Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2020 Dec 11. PMID : 33306283

症例検討編

P.172 掲載の参考文献
1) Oran DP, Topol EJ. Prevalence of asymptomatic SARS-CoV-2 infection : a narrative review. Ann Intern Med. 2020 ; 173 : 362-7. PMID : 32491919
2) Guan WJ, Ni ZY, Hu Y, et al ; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 ; 382 : 1708-20. PMID : 32109013
3) Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 ; 395 : 497-506. Erratum in : Lancet. 2020 Jan 30. PMID : 31986264
4) Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020 ; 382 : 1199-207. PMID : 31995857
5) Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 ; 395 : 497-506. Erratum in : Lancet. 2020 Jan 30. PMID : 31986264
7) Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med. 2020 ; 382 : e38. PMID : 32268022
8) Bowles L, Platton S, Yartey N, et al. Lupus anticoagulant and abnormal coagulation tests in patients with Covid-19. N Engl J Med. 2020 ; 383 : 288-90. PMID : 32369280
9) Kucirka LM, Lauer SA, Laeyendecker O, et al. Variation in false-negative rate of reverse transcriptase polymerase chain reaction-based SARS-CoV-2 tests by time since exposure. Ann Intern Med. 2020 ; 173 : 262-7. PMID : 32422057
10) Pan F, Ye T, Sun P, et al. Time course of lung changes at chest CT during recovery from coronavirus disease 2019 (COVID-19). Radiology. 2020 ; 295 : 715-21. PMID : 32053470
11) Ai T, Yang Z, Hou H, et al. Correlation of chest CT and RT-PCR testing for coronavirus disease 2019 (COVID-19) in China : a report of 1014 cases. Radiology. 2020 ; 296 : E32-40. PMID : 32101510
12) Gattinoni L, Chiumello D, Rossi S. COVID-19 pneumonia : ARDS or not? Crit Care. 2020 ; 24 : 154. PMID : 32299472
13) Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China : a descriptive study. Lancet Infect Dis. 2020 ; 20 : 425-34. PMID : 32105637
16) Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 ; 395 : 497-506. Erratum in : Lancet. 2020 Jan 30. PMID : 31986264
17) He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med. 2020 ; 26 : 672-5. Erratum in : Nat Med. 2020 ; 26 : 1491-3. PMID : 32296168
18) Cheng HY, Jian SW, Liu DP, et al ; Taiwan COVID-19 Outbreak Investigation Team. Contact tracing assessment of COVID-19 transmission dynamics in Taiwan and risk at different exposure periods before and after symptom onset. JAMA Intern Med. 2020 ; 180 : 1156-63. PMID : 32356867
19) Xiao AT, Tong YX, Zhang S. Profile of RT-PCR for SARS-CoV-2 : a preliminary study from 56 COVID-19 patients. Clin Infect Dis. 2020 ; 71 : 2249-51. PMID : 32306036
20) Wolfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020 ; 581 : 465-9. PMID : 32235945
21) Bullard J, Dust K, Funk D, et al. Predicting infectious SARS-CoV-2 from diagnostic samples. Clin Infect Dis. 2020 May 22 : ciaa638. PMID : 32442256
22) Xie X, Zhong Z, Zhao W, et al. Chest CT for typical coronavirus disease 2019 (COVID-19) pneumonia : relationship to negative RT-PCR testing. Radiology. 2020 ; 296 : E41-5. PMID : 32049601
24) ESCMID Sore Throat Guideline Group, Pelucchi C, Grigoryan L, Galeone C, et al. Guideline for the management of acute sore throat. Clin Microbiol Infect. 2012 ; 18 Suppl 1 : 1-28. PMID : 22432746
25) McIsaac WJ, White D, Tannenbaum D, et al. A clinical score to reduce unnecessary antibiotic use in patients with sore throat. CMAJ. 1998 ; 158 : 75-83. PMID : 9475915
26) 厚生労働省. 新型コロナウイルス感染症 (COVID-19) 診療の手引き 第4版. 2020.
27) Ji D, Zhang D, Xu J, et al. Prediction for progression risk in patients with COVID-19 pneumonia : the CALL score. Clin Infect Dis. 2020 ; 71 : 1393-9. PMID : 32271369
28) Liang W, Liang H, Ou L, et al ; China Medical Treatment Expert Group for COVID-19. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern Med. 2020 ; 180 : 1081-9. PMID : 32396163
29) RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19-preliminary report. N Engl J Med. 2020 Jul 17 : NEJMoa2021436. PMID : 32678530
30) Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020 ; 368 : 473-4. PMID : 32303591
31) Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China : a retrospective cohort study. Lancet. 2020 ; 395 : 1054-62. Erratum in : Lancet. 2020 ; 395 : 1038. Erratum in : Lancet. 2020 ; 395 : 1038. PMID : 32171076
32) Malgie J, Schoones JW, Pijls BG. Decreased mortality in COVID-19 patients treated with tocilizumab : a rapid systematic review and meta-analysis of observational studies. Clin Infect Dis. 2020 Sep 23:ciaa1445. PMID : 32964913
33) Aziz M, Haghbin H, Abu Sitta E, et al. Efficacy of tocilizumab in COVID-19 : a systematic review and meta-analysis. J Med Virol. 2020 Sep 12. PMID : 32918755
34) Zhao J, Cui W, Tian BP. Efficacy of tocilizumab treatment in severely ill COVID-19 patients. Crit Care. 2020 ; 24 : 524. PMID : 32854738

最近チェックした商品履歴

Loading...